Towards Structural Studies of Aminopeptidases in Antigen Processing
Project Number7R21AI068831-03
Contact PI/Project LeaderGUO, HWAI-CHEN
Awardee OrganizationUNIVERSITY OF MASSACHUSETTS LOWELL
Description
Abstract Text
DESCRIPTION (provided by applicant): Antigen processing is an integral part of cell-mediated immune surveillance and responses that involve MHC- restriction and T cell recognition. Processed antigenic peptides, when presented on cell surface by MHC molecules to T cells, serve as identity tags to be monitored by our immune system. Thus antigen processing and presentation influence the response of an individual to infectious organisms and has been implicated in the susceptibility to diseases and to the development of autoimmunity. One effective way the immune system eliminates virus-infected or malignant cells is to mount a cytotoxic reaction that result in lysis of target cells. This antiviral mechanism generally involves MHC class I molecules to bind peptides processed from viral proteins synthesized within infected cells, and present those peptides to cytotoxic T lymphocytes (CTLs), which can eliminate the infected cells and thus eliminate potential sources of new viral production. Therefore, understanding the mechanism of antigen processing is critical to fight against various pathogens. For an epitope to be recognized by T cells, foreign antigens need to be processed into short peptides with proper sizes in order to form physical complexes with MHC molecules. The precursors of class I antigenic peptides are generated mainly by proteasomes in the cytosol, and are then transported into the lumen of the endoplasmic reticulum (ER) by transporters associated with antigen processing (TAP). Recently, an aminopeptidase inside the ER, named ERAAP, has been identified to be one missing link that trims peptide precursors and generates the final N-termini of class I-restricted epitopes. Our recent success in expressing and purifying active ERAAP enzyme, and obtaining crystals in the preliminary crystallization screens, have brought about the exciting possibility of providing high-resolution structural information for this critical enzyme. In this exploratory (R21) project, we propose to purify crystallographic quality and quantity of ERAAP, its subdomains, and complexes for biochemical characterization and growing diffraction-quality crystals, with the long-term goal of obtaining high-resolution structures of ERAAP. PUBLIC HEALTH RELEVANCE: Biochemical information and diffraction-quality crystals obtained in this proposal will enable high-resolution structural analyses of ERAAP to enhance our understanding of the mechanisms of antigen processing. This structural information is necessary for the development of protective strategies for biodefense and is thus critical to public health.
National Institute of Allergy and Infectious Diseases
CFDA Code
701
DUNS Number
956072490
UEI
LTNVSTJ3R6D5
Project Start Date
19-June-2009
Project End Date
31-May-2012
Budget Start Date
01-February-2011
Budget End Date
31-May-2012
Project Funding Information for 2010
Total Funding
$113,898
Direct Costs
$75,429
Indirect Costs
$38,469
Year
Funding IC
FY Total Cost by IC
2010
National Institute of Allergy and Infectious Diseases
$113,898
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R21AI068831-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R21AI068831-03
Patents
No Patents information available for 7R21AI068831-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R21AI068831-03
Clinical Studies
No Clinical Studies information available for 7R21AI068831-03
News and More
Related News Releases
No news release information available for 7R21AI068831-03
History
No Historical information available for 7R21AI068831-03
Similar Projects
No Similar Projects information available for 7R21AI068831-03